In Brief for Feb. 8, 2023

Narrow Focus Allows Pragmatica-Lung Trial to Minimize Eligibility Criteria, Significantly Reduce Data Collection, Researcher Says

Pragmatic Approach to Trial Design Born from Lung-MAP Substudy

In Brief for April 26, 2023

In Brief for May 24, 2023

In Brief for June 28, 2023

In Brief for July 26, 2023

US Approves Osimertinib with Chemotherapy for EGFR+ NSCLC; Approvals Pending in Other Countries

US FDA Approves Frontline Amivantamab Combination for Patients with EGFR exon 20 Insertion-mutated NSCLC

Regulating Artificial Intelligence

US FDA Grants Breakthrough Therapy Designation for Novel TKI Targeting HER2, EGFR

US Food and Drug Administration Accepts New Drug Application for Ensartinib